Highly selective and sensitive measurement of active forms of FGF21 using novel immunocapture enrichment with LC–MS/MS

Papers of special note have been highlighted as: • of interest

References

• 1 Nishimura T, Nakatake Y, Konishi M, Itoh N. Identification of a novel FGF, FGF-21, preferentially expressed in the liver. Biochim. Biophys. Acta 1492(1), 203–206 (2000). • Background introduction of FGF21.
  Medline CASGoogle Scholar
• 2 Muise ES, Azzolina B, Kuo DW et al. Adipose fibroblast growth factor 21 is upregulated by peroxisome proliferator-activated receptor gamma and altered metabolic states. Mol. Pharmacol. 74(2), 403–412 (2008).
  Medline CASGoogle Scholar
• 3 Kharitonenkov A, Wroblewski VJ, Koester A et al. The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21. Endocrinol. 148(2), 774–781 (2007).
  Medline CASGoogle Scholar
• 4 Hansen BC. Investigation and treatment of Type 2 diabetes in nonhuman primates. Methods Mol. Biol. 933, 177–185 (2012).
  Medline CASGoogle Scholar
• 5 Kharitonenkov A, Shiyanova TL, Koester A et al. FGF-21 as a novel metabolic regulator. J. Clin. Invest. 115(6), 1627–1635 (2005).
  Medline CASGoogle Scholar
• 6 Degirolamo C, Sabba C, Moschetta A. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat. Rev. Drug Discov. 15(1), 51–69 (2016).
  Medline CASGoogle Scholar
• 7 Woo YC, Xu A, Wang Y, Lam KS. Fibroblast growth factor 21 as an emerging metabolic regulator: clinical perspectives. Clin. Endocrinol. (Oxf.) 78(4), 489–496 (2013).
  Medline CASGoogle Scholar
• 8 Kharitonenkov A, Adams AC. Inventing new medicines: the FGF21 story. Mol. Metab. 3(3), 221–229 (2014).
  Medline CASGoogle Scholar
• 9 Xu J, Lloyd DJ, Hale C et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure and improves insulin sensitivity in diet-induced obese mice. Diabetes 58(1), 250–259 (2009).
  Medline CASGoogle Scholar
• 10 Gaich G, Chien JY, Fu H et al. The effects of LY2405319, an FGF21 analog, in obese human subjects with Type 2 diabetes. Cell Metab. 18(3), 333–340 (2013).
  Medline CASGoogle Scholar
• 11 Adams AC, Halstead CA, Hansen BC et al. LY2405319, an engineered FGF21 variant, improves the metabolic status of diabetic monkeys. PLoS ONE 8(6), e65763 (2013).
  Medline CASGoogle Scholar
• 12 Mu J, Pinkstaff J, Li Z et al. FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents. Diabetes 61(2), 505–512 (2012).
  Medline CASGoogle Scholar
• 13 Wang H, Xiao Y, Fu L et al. High-level expression and purification of soluble recombinant FGF21 protein by SUMO fusion in Escherichia coli. BMC Biotechnol. 10, 14 (2010).
  MedlineGoogle Scholar
• 14 Veniant MM, Komorowski R, Chen P et al. Long-acting FGF21 has enhanced efficacy in diet-induced obese mice and in obese rhesus monkeys. Endocrinology 153(9), 4192–4203 (2012).
  Medline CASGoogle Scholar
• 15 Suzuki M, Lee AY, Vazquez-Medina JP, Viscarra JA, Crocker DE, Ortiz RM. Plasma FGF21 concentrations, adipose fibroblast growth factor receptor-1 and beta-klotho expression decrease with fasting in northern elephant seals. Gen. Comp. Endocrinol. 216, 86–89 (2015).
  Medline CASGoogle Scholar
• 16 Zhang X, Yeung DC, Karpisek M et al. Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans. Diabetes 57(5), 1246–1253 (2008).
  Medline CASGoogle Scholar
• 17 Kurosu H, Choi M, Ogawa Y et al. Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determine metabolic activity of FGF19 and FGF21. J. Biol. Chem. 282(37), 26687–26695 (2007).
  Medline CASGoogle Scholar
• 18 Ogawa Y, Kurosu H, Yamamoto M et al. BetaKlotho is required for metabolic activity of fibroblast growth factor 21. Proc. Natl Acad. Sci. USA 104(18), 7432–7437 (2007).
  Medline CASGoogle Scholar
• 19 Suzuki M, Uehara Y, Motomura-Matsuzaka K et al. BetaKlotho is required for fibroblast growth factor (FGF) 21 signaling through FGF receptor (FGFR) 1c and FGFR3c. Mol. Endocrinol. 22(4), 1006–1014 (2008).
  Medline CASGoogle Scholar
• 20 Yang C, Jin C, Li X, Wang F, Mckeehan WL, Luo Y. Differential specificity of endocrine FGF19 and FGF21 to FGFR1 and FGFR4 in complex with KLB. PLoS ONE 7(3), e33870 (2012).
  Medline CASGoogle Scholar
• 21 Yie J, Wang W, Deng L et al. Understanding the physical interactions in the FGF21/FGFR/beta-Klotho complex: structural requirements and implications in FGF21 signaling. Chem. Biol. Drug Des. 79(4), 398–410 (2012).
  Medline CASGoogle Scholar
• 22 Zhen EY, Jin Z, Ackermann BL, Thomas MK, Gutierrez JA. Circulating FGF21 proteolytic processing mediated by fibroblast activation protein. Biochem. J. 473(5), 605–614 (2016).
  Medline CASGoogle Scholar
• 23 Umberger TS, Sloan JH, Chen J et al. Novel sandwich immunoassays for the measurement of total and active FGF21. Bioanalysis 6(24), 3283–3293 (2014).
  CASGoogle Scholar
• 24 Hager T, Spahr C, Xu J, Salimi-Moosavi H, Hall M. Differential enzyme-linked immunosorbent assay and ligand-binding mass spectrometry for analysis of biotransformation of protein therapeutics: application to various FGF21 modalities. Anal. Chem. 85(5), 2731–2738 (2013).
  Medline CASGoogle Scholar
• 25 Yie J, Hecht R, Patel J et al. FGF21 N- and C-termini play different roles in receptor interaction and activation. FEBS Lett. 583(1), 19–24 (2009).
  Medline CASGoogle Scholar
• 26 Jones BR, Schultz GA, Eckstein JA, Ackermann BL. Surrogate matrix and surrogate analyte approaches for definitive quantitation of endogenous biomolecules. Bioanalysis 4(19), 2343–2356 (2012). • A comprehensive summary of using surrogate matrix and surrogate analyte approaches for biomarker quantitation.
  CASGoogle Scholar
• 27 Houghton R, Horro Pita C, Ward I, Macarthur R. Generic approach to validation of small-molecule LC–MS/MS biomarker assays. Bioanalysis 1(8), 1365–1374 (2009).
  CASGoogle Scholar
• 28 Torsetnes SB, Nordlund MS, Paus E, Halvorsen TG, Reubsaet L. Digging deeper into the field of the small-cell-lung cancer tumor marker ProGRP: a method for differentiation of its isoforms. J. Proteome Res. 12(1), 412–420 (2013).
  Medline CASGoogle Scholar
• 29 Booth B. When do you need a validated assay? Bioanalysis 3(24), 2729–2730 (2011).
  CASGoogle Scholar
• 30 Van Den Broek I, Sparidans RW, Schellens JH, Beijnen JH. Quantitative bioanalysis of peptides by liquid chromatography coupled to (tandem) mass spectrometry. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 872(1–2), 1–22 (2008). • A review of the application of LC–MS/MS to the quantitative analysis of peptides.
  Medline CASGoogle Scholar
• 31 Ghosh S, Bull HB. Adsorbed films of bovine serum albumin: tensions at air-water surfaces and paraffin-water interfaces. Biochim. Biophys. Acta 66, 150–157 (1963).
  Medline CASGoogle Scholar
• 32 Angelin B, Larsson TE, Rudling M. Circulating fibroblast growth factors as metabolic regulators – a critical appraisal. Cell Metab. 16(6), 693–705 (2012).
  Medline CASGoogle Scholar